Toyama and Eisai withdraw Japanese iguratimod filing for RA
This article was originally published in Scrip
Toyama Chemical and development partner Eisai have temporarily withdrawn a Japanese approval filing for the rheumatoid arthritis (RA) therapy iguratimod (T-614), citing a need for additional clinical studies.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.